Welcome to your daily round-up of everything happening in the world of neurorehabilitation.
Research news
TNIK as a therapeutic target for Alzheimer’s
A new paper in Trends in Pharmacological Sciences from researchers at generative artificial intelligence- and robotics-powered clinical stage drug discovery company Insilico Medicine and ETH Zurich reveals the broad potential of TNIK as a therapeutic target for some of the most pervasive aging-related diseases, including fibrosis, cancer, obesity, and Alzheimer’s. The findings could guide the development of new therapeutics. The lead drug in Insilico’s pipeline, INS018_055, is an AI-designed TNIK inhibitor being advanced as a treatment for the deadly lung disease idiopathic pulmonary fibrosis (IPF) and is currently in Phase II trials with patients.
Early vs late anticoagulation in ischemic stroke with atrial fibrillation
A new study has revealed that the treatment effect of early direct oral anticoagulant initiation did not differ in people with minor, moderate, or major stroke assessed by brain imaging. Early treatment was not associated with a higher rate of adverse events, especially symptomatic intracranial haemorrhage, for any infarct size, including major stroke.
Prenatal exposure to air pollution associated with increased mental health risks
A baby’s exposure to air pollution while in the womb is associated with the development of certain mental health problems once the infant reaches adolescence, new research has found. The University of Bristol-led study, published in JAMA Network Open, examined the long-term mental health impact of early-life exposure to air and noise pollution.
Company and financial neuro-rehab news
Advancing SAT-3247 in clinical trial development for Duchenne Muscular Dystrophy
Satellos Bioscience Inc., a public biotech company developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders, has announced the formation of a Clinical Advisory Board comprised of distinguished clinical research leaders and experts in drug development in genetic muscle disorders, including Duchenne muscular dystrophy.
TIGER Study: Survival results for newly Diagnosed Glioblastoma Patients
Novocure has released topline efficacy and safety data from the TIGER study investigating the use of Tumour Treating Fields (TTFields) therapy in routine clinical care in the treatment of patients with newly diagnosed glioblastoma (GBM) in Germany. Median overall survival for patients treated with TTFields therapy was 19.6 months (95% CI, 17.9-22.4). Median progression-free survival was 10.2 months (95% CI, 9.4-11.4). TTFields therapy use was not associated with an increase in systemic toxicity and was well tolerated. The outcomes observed in the TIGER study are consistent with the survival and safety results from Novocure’s phase 3 EF-14 clinical trial.
Technology news
How engineers are trying to build better brain implants
The Institution of Mechanical Engineers reports on how an injection of cash into the commercialisation of brain-computer interface technology is promising leaps and bounds for the future of healthcare.
